Adlai Nortye
ANL | NASDAQ
$10.03
-$0.58 (-5.47%)
At close: Nov 16, 2026, 4:00 PM ET
$10.03
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Adlai Nortye Company Profile
Company profile explainedCompany Profile
Adlai Nortye Ltd. (ANL) is a clinical-stage biotechnology firm dedicated to the research and development of innovative pharmaceutical products. Their flagship compound, AN2025, a pan-phosphoinositide 3-kinase inhibitor, is currently undergoing Phase III clinical trials. It is being investigated as a potential treatment for recurrent or metastatic head and neck squamous cell carcinomas. The company's pipeline also features AN0025, a small molecule prostaglandin E receptor 4 antagonist designed to modulate the tumor microenvironment. This candidate is in Phase Ib clinical trials, exploring its efficacy in treating various conditions, including: recurrent non-small cell lung cancer; urothelial cancer (post-anti-PD-1/PD-L1 treatments); recurrent triple-negative breast cancer; microsatellite stable colorectal cancer; and cervical cancer (following standard-of-care treatments). Additionally, ANL is developing AN4005, an oral small-molecule PD-L1 inhibitor. This drug, which is in Phase I clinical trials, aims to induce and stabilize PD-L1 dimerization to disrupt the interaction between PD-1 and PD-L1. Beyond their clinical programs, Adlai Nortye has early-stage research candidates such as AN8025, a multifunctional antibody that acts as a modulator of T cells and antigen-presenting cells, and AN9025, an oral small molecule pan-KRAS inhibitor. Established in 2004, the company's headquarters are situated in Grand Cayman, Cayman Islands.
Key Executives
| Name | Position |
|---|---|
| Yang Lu | Co- Founder, Chief Executive Officer & Chairman |
| Xiaofeng Ye | Chief Financial Officer |
| Chen Yang | Head of HR & Administration & Government Affairs |
| Christopher Liu | Head of Investor Relations & Public Relations |
| Donghui Yang | Chairman of the Greater China Region |
| Nanhai He | Head of Discovery |
| Ngai Chiu Tse | President & Head of Research & Development |
| Zhiyong Yu | Vice President of Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 28, 2026 | 6-K | Filing |
| Oct 15, 2026 | 6-K | Filing |
| Oct 01, 2026 | 4 | Filing |
| Sep 30, 2026 | 6-K | Filing |
| Sep 30, 2026 | 6-K | Filing |
| Sep 24, 2026 | 4 | Filing |
| Sep 15, 2026 | EFFECT | Filing |
| Sep 11, 2026 | S-8 POS | Filing |
| Sep 11, 2026 | S-8 POS | Filing |
| Sep 11, 2026 | POS AM | Filing |
Adlai Nortye
| Country | Singapore |
| IPO Date | Sep 29, 2023 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 109 |
| CEO | Yang Lu |
Contact Details
77 Robinson Road, #20-01, Robinson 77 Singapore 068896 Singapore
Stock Details
| Ticker Symbol | ANL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001944552 |
| CUSIP Number | 00704R109 |
| ISIN Number | US00704R1095 |
| SIC Code | 2834 |
Add to Watchlist
Select watchlists to add or remove ANL